{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T04:58:46Z","timestamp":1758862726266,"version":"3.38.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,7]]},"DOI":"10.7759\/cureus.80204","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T13:22:56Z","timestamp":1741353776000},"source":"Crossref","is-referenced-by-count":2,"title":["Antipsychotic Polypharmacy for Treatment Resistant Schizoaffective Disorder: A Case Report"],"prefix":"10.7759","author":[{"given":"Sydney E","family":"Moriarty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paria","family":"Parhami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Galicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. American Psychiatric Association, Washington DC; 2013."},{"key":"ref2","article-title":"Schizoaffective disorder","author":"Wy TJ","year":"2023","unstructured":"Wy TJ, Saadabadi A. Schizoaffective disorder. StatPearls [Internet]. StatPearls Publishing, Treasure Island; 2023."},{"key":"ref3","article-title":"Impact of the DSM-IV to DSM-5 Changes on the National Survey on Drug Use and Health","year":"2016","unstructured":"Impact of the DSM-IV to DSM-5 Changes on the National Survey on Drug Use and Health. Substance Abuse and Mental Health Services Administration, Rockville; 2016."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01556-4","article-title":"Antipsychotic polypharmacy for the management of schizophrenia: evidence and recommendations","volume":"81","author":"L\u00e4hteenvuo M","year":"2021","unstructured":"L\u00e4hteenvuo M, Tiihonen J. Antipsychotic polypharmacy for the management of schizophrenia: evidence and recommendations. Drugs. 2021, 81:1273-84. 10.1007\/s40265-021-01556-4","journal-title":"Drugs"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-050911-161504","article-title":"Update on typical and atypical antipsychotic drugs","volume":"64","author":"Meltzer HY","year":"2013","unstructured":"Meltzer HY. Update on typical and atypical antipsychotic drugs. Annu Rev Med. 2013, 64:393-406. 10.1146\/annurev-med-050911-161504","journal-title":"Annu Rev Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2018.08.016","article-title":"Treatment resistant schizophrenia: clinical, biological, and therapeutic perspectives","volume":"131","author":"Nucifora FC Jr","year":"2019","unstructured":"Nucifora FC Jr, Woznica E, Lee BJ, Cascella N, Sawa A. Treatment resistant schizophrenia: clinical, biological, and therapeutic perspectives. Neurobiol Dis. 2019, 131:104257. 10.1016\/j.nbd.2018.08.016","journal-title":"Neurobiol Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.115.177261","article-title":"Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis","volume":"209","author":"Siskind D","year":"2016","unstructured":"Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016, 209:385-92. 10.1192\/bjp.bp.115.177261","journal-title":"Br J Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00779-5","article-title":"Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview","volume":"35","author":"Correll CU","year":"2021","unstructured":"Correll CU, Kim E, Sliwa JK, et al.. Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview. CNS Drugs. 2021, 35:39-59. 10.1007\/s40263-020-00779-5","journal-title":"CNS Drugs"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"The American Psychiatric Association Practice Guideline for the treatment of patients with schizophrenia","volume":"177","author":"Keepers GA","year":"2020","unstructured":"Keepers GA, Fochtmann LJ, Anzia JM, et al.. The American Psychiatric Association Practice Guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020, 177:868-72. 10.1176\/appi.ajp.2020.177901","journal-title":"Am J Psychiatry"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2024.07.035","article-title":"Efficacy and tolerability of antipsychotic polypharmacy for schizophrenia spectrum disorders. A systematic review and meta-analysis of individual patient data","volume":"272","author":"Lochmann van Bennekom MW","year":"2024","unstructured":"Lochmann van Bennekom MW, IntHout J, Gijsman HJ, et al.. Efficacy and tolerability of antipsychotic polypharmacy for schizophrenia spectrum disorders. A systematic review and meta-analysis of individual patient data. Schizophr Res. 2024, 272:1-11. 10.1016\/j.schres.2024.07.035","journal-title":"Schizophr Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20230180","article-title":"An argument for antipsychotic polypharmacy","volume":"180","author":"Buchanan RW","year":"2023","unstructured":"Buchanan RW, Kreyenbuhl J. An argument for antipsychotic polypharmacy. Am J Psychiatry. 2023, 180:334-6. 10.1176\/appi.ajp.20230180","journal-title":"Am J Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v65n1013","article-title":"Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000","volume":"65","author":"Ganguly R","year":"2004","unstructured":"Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry. 2004, 65:1377-88. 10.4088\/jcp.v65n1013","journal-title":"J Clin Psychiatry"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2012.03.018","article-title":"Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009","volume":"138","author":"Gallego JA","year":"2012","unstructured":"Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012, 138:18-28. 10.1016\/j.schres.2012.03.018","journal-title":"Schizophr Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2009.01.002","article-title":"The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis","volume":"109","author":"Tiihonen J","year":"2009","unstructured":"Tiihonen J, Wahlbeck K, Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2009, 109:10-4. 10.1016\/j.schres.2009.01.002","journal-title":"Schizophr Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12495","article-title":"A new rapid titration protocol for lamotrigine that reduces the risk of skin rash","volume":"6","author":"Jang Y","year":"2021","unstructured":"Jang Y, Moon J, Kim N, et al.. A new rapid titration protocol for lamotrigine that reduces the risk of skin rash. Epilepsia Open. 2021, 6:394-401. 10.1002\/epi4.12495","journal-title":"Epilepsia Open"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2016.11.012","article-title":"Adjunctive minocycline for schizophrenia: a meta-analysis of randomized controlled trials","volume":"27","author":"Xiang YQ","year":"2017","unstructured":"Xiang YQ, Zheng W, Wang SB, et al.. Adjunctive minocycline for schizophrenia: a meta-analysis of randomized controlled trials. Eur Neuropsychopharmacol. 2017, 27:8-18. 10.1016\/j.euroneuro.2016.11.012","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065250","article-title":"Minocycline as treatment for psychiatric and neurological conditions: a systematic review and meta-analysis","volume":"24","author":"Panizzutti B","year":"2023","unstructured":"Panizzutti B, Skvarc D, Lin S, et al.. Minocycline as treatment for psychiatric and neurological conditions: a systematic review and meta-analysis. Int J Mol Sci. 2023, 24:10.3390\/ijms24065250","journal-title":"Int J Mol Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S125367","article-title":"Efficacy and tolerability of topiramate-augmentation therapy for schizophrenia: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Okuyama Y","year":"2016","unstructured":"Okuyama Y, Oya K, Matsunaga S, Kishi T, Iwata N. Efficacy and tolerability of topiramate-augmentation therapy for schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Neuropsychiatr Dis Treat. 2016, 12:3221-36. 10.2147\/NDT.S125367","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.2021.19.1.117","article-title":"Clinical usefulness of amisulpride add-on therapy in schizophrenia patients without treatment response to second-generation antipsychotics","volume":"19","author":"Kang SG","year":"2021","unstructured":"Kang SG, Cho SE, Na KS, Pae CU, Cho SJ. Clinical usefulness of amisulpride add-on therapy in schizophrenia patients without treatment response to second-generation antipsychotics. Clin Psychopharmacol Neurosci. 2021, 19:117-24. 10.9758\/cpn.2021.19.1.117","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1395524","article-title":"Augmentation with amisulpride for schizophrenic patients non-responsive to risperidone monotherapy","volume":"48","author":"Toledo-Romero F","year":"2015","unstructured":"Toledo-Romero F, Molina JD, L\u00f3pez-Rodr\u00edguez E, Amorin-D\u00edaz M, Mu\u00f1oz Algar MJ, Aparicio-Castro E. Augmentation with amisulpride for schizophrenic patients non-responsive to risperidone monotherapy. Pharmacopsychiatry. 2015, 48:51-7. 10.1055\/s-0034-1395524","journal-title":"Pharmacopsychiatry"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1279728","article-title":"Augmentation treatment with amisulpride in schizophrenic patients partially responsive to olanzapine","volume":"44","author":"Molina JD","year":"2011","unstructured":"Molina JD, Toledo-Romero F, L\u00f3pez-Rodr\u00edguez E, Amorin-D\u00edaz M, Lerma-Carrillo I, L\u00f3pez-Mu\u00f1oz F. Augmentation treatment with amisulpride in schizophrenic patients partially responsive to olanzapine. Pharmacopsychiatry. 2011, 44:142-7. 10.1055\/s-0031-1279728","journal-title":"Pharmacopsychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/289276-antipsychotic-polypharmacy-for-treatment-resistant-schizoaffective-disorder-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T13:22:59Z","timestamp":1741353779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/289276-antipsychotic-polypharmacy-for-treatment-resistant-schizoaffective-disorder-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.80204","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,7]]}}}